EA037067B1 - Селективные ингибиторы jak1 - Google Patents

Селективные ингибиторы jak1 Download PDF

Info

Publication number
EA037067B1
EA037067B1 EA201991700A EA201991700A EA037067B1 EA 037067 B1 EA037067 B1 EA 037067B1 EA 201991700 A EA201991700 A EA 201991700A EA 201991700 A EA201991700 A EA 201991700A EA 037067 B1 EA037067 B1 EA 037067B1
Authority
EA
Eurasian Patent Office
Prior art keywords
fluoro
methylsulfonyl
phenyl
indol
amino
Prior art date
Application number
EA201991700A
Other languages
English (en)
Russian (ru)
Other versions
EA201991700A1 (ru
Inventor
Карл Магнус Нильссон
Анника Биргитта Маргарета Остранд
Анна Ингрид Кристина Берггрен
Йохан Р. Йоханссон
Матти Юхани Лепистё
Самир Пралхад Каваткар
Цибинь Су
Джейсон Грант Кеттл
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of EA201991700A1 publication Critical patent/EA201991700A1/ru
Publication of EA037067B1 publication Critical patent/EA037067B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EA201991700A 2017-01-17 2018-01-16 Селективные ингибиторы jak1 EA037067B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762447057P 2017-01-17 2017-01-17
PCT/EP2018/051038 WO2018134213A1 (en) 2017-01-17 2018-01-16 Jak1 selective inhibitors

Publications (2)

Publication Number Publication Date
EA201991700A1 EA201991700A1 (ru) 2020-01-28
EA037067B1 true EA037067B1 (ru) 2021-02-02

Family

ID=61024756

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991700A EA037067B1 (ru) 2017-01-17 2018-01-16 Селективные ингибиторы jak1

Country Status (38)

Country Link
US (4) US10961228B2 (https=)
EP (2) EP3571192B1 (https=)
JP (3) JP6986086B2 (https=)
KR (2) KR102585048B1 (https=)
CN (2) CN115925693B (https=)
AR (1) AR110753A1 (https=)
AU (1) AU2018209667B2 (https=)
CA (1) CA3049175A1 (https=)
CL (1) CL2019001993A1 (https=)
CO (1) CO2019007888A2 (https=)
CR (1) CR20190332A (https=)
DK (1) DK3571192T3 (https=)
DO (1) DOP2019000184A (https=)
EA (1) EA037067B1 (https=)
EC (1) ECSP19051352A (https=)
ES (1) ES2938648T3 (https=)
FI (1) FI3571192T3 (https=)
HR (1) HRP20230069T1 (https=)
HU (1) HUE061064T2 (https=)
IL (1) IL267851B (https=)
JO (1) JOP20190174B1 (https=)
LT (1) LT3571192T (https=)
MA (1) MA47301B1 (https=)
MX (2) MX390625B (https=)
MY (1) MY199735A (https=)
NI (1) NI201900077A (https=)
PE (1) PE20191108A1 (https=)
PH (1) PH12019501639B1 (https=)
PL (1) PL3571192T3 (https=)
PT (1) PT3571192T (https=)
RS (1) RS63981B1 (https=)
SG (1) SG11201906222WA (https=)
SI (1) SI3571192T1 (https=)
SM (1) SMT202300051T1 (https=)
TW (1) TWI753089B (https=)
UA (1) UA124246C2 (https=)
WO (1) WO2018134213A1 (https=)
ZA (1) ZA201906875B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102585048B1 (ko) * 2017-01-17 2023-10-05 아스트라제네카 아베 Jak1 선택적 억제제
DK3514153T3 (da) 2017-01-26 2021-09-27 Hanmi Pharm Ind Co Ltd Pyrimidinforbindelse og farmaceutisk anvendelse deraf
SG11202100240RA (en) * 2018-07-18 2021-02-25 Astrazeneca Ab A xinafoate salt of a jak inhibiting compound
KR101954370B1 (ko) 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
CA3113732C (en) * 2018-09-21 2023-07-11 Shanghai Ennovabio Pharmaceuticals Co., Ltd. Aromatic heterocyclic compound with kinase inhibitory activity
PH12021551985A1 (en) 2019-02-22 2022-08-22 Hanmi Pharmaceutical Co Ltd Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia
TWI910107B (zh) * 2019-04-19 2026-01-01 大陸商迪哲(江蘇)醫藥股份有限公司 Jak1選擇性激酶抑制劑
EA202290154A1 (ru) 2019-06-27 2022-03-29 Ханми Фарм. Ко., Лтд. Фармацевтическая композиция для лечения острого миелоидного лейкоза, содержащая ингибитор flt3 и химиотерапевтические агенты
CN115916764B (zh) * 2020-04-09 2024-09-20 达萨玛治疗公司 作为sarm1抑制剂的吲唑衍生物
JP7613778B2 (ja) * 2020-11-26 2025-01-15 科輝智薬(深▲セン▼)新薬研究中心有限公司 アミド化合物、医薬組成物およびその使用
BR112023016986A2 (pt) * 2021-02-26 2023-11-07 Tyra Biosciences Inc Compostos de aminopirimidina e métodos de seu uso
US12240836B2 (en) 2022-07-05 2025-03-04 Dong-A St Co., Ltd. Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof
CN115260128B (zh) * 2022-09-21 2022-12-09 苏州凯瑞医药科技有限公司 一种新型jak抑制剂关键中间体的制备方法
EP4648776A1 (en) * 2023-01-11 2025-11-19 Pfizer Inc. Compositions and methods for the treatment and/or prevention of type 1 diabetes
CN115974845B (zh) * 2023-01-19 2024-09-20 奥锐特药业股份有限公司 奥希替尼中间体的制备方法
TW202438061A (zh) * 2023-03-16 2024-10-01 美商英塞特公司 用於治療氣喘之jak1路徑抑制劑
GB202316063D0 (en) 2023-10-20 2023-12-06 Astrazeneca Ab Dosing regime
GB202403369D0 (en) 2024-03-08 2024-04-24 Astrazeneca Ab Process and intermediates for the production of a jak1 inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046416A1 (en) * 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
WO2009118567A2 (en) * 2008-03-26 2009-10-01 The University Of Nottingham Pyrimidines, triazines and their use as pharmaceutical agents
WO2017050938A1 (en) * 2015-09-25 2017-03-30 Astrazeneca Ab Compounds and methods for inhibiting jak

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007004488A (es) * 2004-10-13 2007-09-11 Wyeth Corp Analogos de anilino-pirimidina n-bencenosulfonilo sustituidos.
GB2431927B (en) * 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
CN101421250A (zh) * 2006-01-30 2009-04-29 埃克塞里艾克西斯公司 作为jak-2调节剂的4-芳基-2-氨基-嘧啶或4-芳基-2-氨基烷基-嘧啶及包含它们的药物组合物
JP2010518025A (ja) * 2007-02-05 2010-05-27 アミラ ファーマシューティカルス,インコーポレーテッド 5−リポキシゲナーゼ活性化タンパク質(flap)インヒビターとしての逆インドール
WO2009045700A2 (en) * 2007-10-05 2009-04-09 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
UA110324C2 (en) * 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
PT3354652T (pt) 2010-03-10 2020-07-20 Incyte Holdings Corp Derivados de piperidin-4-ilazetidina como inibidores de jak1
MX2013003019A (es) * 2010-09-15 2013-05-28 Hoffmann La Roche Compuestos de azabenzotiazol, composiciones y metodos de uso.
EP3060234A1 (en) 2013-10-24 2016-08-31 AbbVie Inc. Jak1 selective inhibitor and uses thereof
KR102585048B1 (ko) * 2017-01-17 2023-10-05 아스트라제네카 아베 Jak1 선택적 억제제

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046416A1 (en) * 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
WO2009118567A2 (en) * 2008-03-26 2009-10-01 The University Of Nottingham Pyrimidines, triazines and their use as pharmaceutical agents
WO2017050938A1 (en) * 2015-09-25 2017-03-30 Astrazeneca Ab Compounds and methods for inhibiting jak

Also Published As

Publication number Publication date
MX390625B (es) 2025-03-19
MX2022002976A (es) 2022-04-06
JOP20190174B1 (ar) 2023-09-17
LT3571192T (lt) 2023-02-27
NZ756069A (en) 2025-08-29
MY199735A (en) 2023-11-21
CN115925693B (zh) 2024-11-12
TW201838984A (zh) 2018-11-01
RS63981B1 (sr) 2023-03-31
ES2938648T3 (es) 2023-04-13
EA201991700A1 (ru) 2020-01-28
KR102585048B1 (ko) 2023-10-05
CN110461830B (zh) 2022-11-01
MX2019008435A (es) 2019-09-09
JP7394820B2 (ja) 2023-12-08
JP2022043059A (ja) 2022-03-15
CO2019007888A2 (es) 2019-07-31
JP7626819B2 (ja) 2025-02-04
PT3571192T (pt) 2023-02-21
PE20191108A1 (es) 2019-08-26
DOP2019000184A (es) 2019-08-15
PH12019501639B1 (en) 2023-09-08
US12473272B2 (en) 2025-11-18
JP2020506171A (ja) 2020-02-27
US20190367490A1 (en) 2019-12-05
TWI753089B (zh) 2022-01-21
CR20190332A (es) 2019-09-13
US10961228B2 (en) 2021-03-30
ECSP19051352A (es) 2019-07-31
KR20190104215A (ko) 2019-09-06
SMT202300051T1 (it) 2023-03-17
MA47301B1 (fr) 2023-02-28
CA3049175A1 (en) 2018-07-26
EP4219470A1 (en) 2023-08-02
EP3571192A1 (en) 2019-11-27
AU2018209667B2 (en) 2020-05-07
CN110461830A (zh) 2019-11-15
DK3571192T3 (da) 2023-02-06
NI201900077A (es) 2020-03-18
JP2024010041A (ja) 2024-01-23
UA124246C2 (uk) 2021-08-11
PL3571192T3 (pl) 2023-03-20
WO2018134213A1 (en) 2018-07-26
CL2019001993A1 (es) 2019-12-27
EP3571192B1 (en) 2022-11-30
MA47301A (fr) 2019-11-27
IL267851B (en) 2021-08-31
HRP20230069T1 (hr) 2023-03-17
US20260028329A1 (en) 2026-01-29
MX418519B (es) 2024-12-09
PH12019501639A1 (en) 2020-07-06
KR20230141938A (ko) 2023-10-10
BR112019014526A2 (pt) 2020-02-27
US20210188821A1 (en) 2021-06-24
JOP20190174A1 (ar) 2019-07-14
US20240208947A1 (en) 2024-06-27
ZA201906875B (en) 2021-05-26
HUE061064T2 (hu) 2023-05-28
AR110753A1 (es) 2019-05-02
JP6986086B2 (ja) 2021-12-22
AU2018209667A1 (en) 2019-08-22
SI3571192T1 (sl) 2023-03-31
US11897869B2 (en) 2024-02-13
CN115925693A (zh) 2023-04-07
FI3571192T3 (fi) 2023-03-06
IL267851A (en) 2019-09-26
KR102659213B1 (ko) 2024-04-18
SG11201906222WA (en) 2019-08-27

Similar Documents

Publication Publication Date Title
JP7394820B2 (ja) Jak1選択的阻害剤
JP2023106425A (ja) アミノ酸化合物および使用方法
DK3207043T3 (en) DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR GAMMA
KR20230049584A (ko) 아미노산 화합물을 사용한 호흡기 질환의 치료
HK40098388A (en) Jak1 selective inhibitors
JP7851393B2 (ja) 癌の治療のためのhpk1阻害剤としての置換ピラジン-2-カルボキサミド阻害剤
JP2024527623A (ja) 癌の治療のためのhpk1阻害剤としての置換ピラジン-2-カルボキサミド阻害剤
HK40017725B (en) Jak1 selective inhibitors
HK40017725A (en) Jak1 selective inhibitors
BR112019014526B1 (pt) Composto, composição farmacêutica e uso de um composto no tratamento de uma disfunção relacionada com jak1
HK40016478A (en) Jak1 selective inhibitors
HK40016478B (en) Jak1 selective inhibitors
HK1243402B (en) Dihydropyrrolopyridine inhibitors of ror-gamma
HK1243402A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma